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1. Introduction 
It has been reported that leucine dehydrogenase 
(L-1eucine:NAD oxidoreductase [deaminating] EC 
class 1.4.1) from Bacillus sphaericus IF0 3525 was 
highly inhibitory to Ehrlich ascites carcinoma in vivo 
[l 1. The present report describes experiments which 
indicate that a homogeneous preparation of this 
enzyme did not inhibit growth of Ehrlich ascites car- 
cinoma or the Taper liver tumor. Furthermore, no 
significant change in plasma leucine levels was observed 
in mice Ieceivlng injections of this enzyme. The lack 
of in vivo effectiveness of B. sphaericus leucine dehy- 
drogenase may be explained on the basis of its pH- 
activity profile and equilibrium considerations. 
2. Experimental 
Leucine dehydrogenase (L-1euciue:NAD oxido- 
reductase [deaminating] EC class 1.4.1) which was 
purified to homogeneity as previously described [2] 
was a gift from Dr. Kenji Soda, Kyoto University. 
The enzyme was dialyzed overnight at 4°C against 
500 vol. of 0.01 M sodium phosphate buffer (pH 7.6) 
containing 0.9% NaCl. The concentration of the 
enzyme solution following dialysis was adjusted to 
0.8 mg enzyme protein/ml. After dialysis the enzyme 
was stable for at least 4 days at 4°C. Fresh enzyme 
solution for injection was prepared every third day 
and stored at 4°C. 
Leucine dehydrogenase was assayed by measuring 
the rate of increase in absorbance at 340 nm resulting 
from reduction of NAD. The reaction mixture con- 
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sisted of 125 I.tmoles glycine-KCl-KOH buffer 
(pH 11.3), 10 Bmoles Lleucine and 1.25 pmoles 
/3-NAD in a total vol. of 0.8 ml. The reaction was 
initiated by the addition of 5 ~1 enzyme solution 
(containing 16 ~.cg protein) and the increase iu 
absorbance at 340 nm was followed on a Gilford 
240 spectrophotometer. The temperature was 25°C. 
One unit (U) of activity is the amount of enzyme 
which causes the increase in 1 .O in absorbance per 
minute at 340 nm. 
The ascites forms of Ehrlich carcinoma nd Taper 
liver tumor were carried in BD2FI tiice. Female 
mice weighing 19-22 g were inoculated intra- 
peritoneally with 10’ cells on day 0 and treated for 
14 days with leucine dehydrogenase, beginning on 
day 1. 
Amino acid analyses were performed on a Beckman 
Model 119 amino acid analyzer using lithium citrate 
buffers for the acidic and neutral amino acids [3-51. 
Blood for determination of plasma mino acids was 
obtained from mice by the orbital bleeding technique 
[3]. Special care was taken to minimize amino acid 
alterations during the processing of blood and plasma 
samples for amino acid analysis [3]. 
3. Results and discussion 
The leucine dehydrogenase was assayed prior to 
injection and found to contain 80 units (U) per mg 
protein. Table 1 shows that daily injection of leucine 
dehydrogenase for 14 days at 4 mg/kg body weight 
did not significantly alter the median survival time 
of mice bearing the Ehrlich ascites carcinoma or the 
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Table 1 
Effect of leucine dehydrogenase treatment on tumor growth 
Tumor 
Taper liver* 4 
Ehrlich carcinoma* 4 
Ehrlich carcinoma* 4 
Ehrlich carcinoma* 8 
Ehrlich carcinoma* 16 
Ehrlich carcinoma** 4-16 
Enzyme dose 
mg/kg/day 
Median survival day of mice (range) 
Control Treated 
18(14-21) 18(15-33) 
20(19-23) 19(18-25) 
18(16-19) 16(14-17) 
18(16-19) 22(18-24) 
18(16-19) 19(13-22) 
19(16-23) 19(14-25) 
* There were 5 mice in each treatment group. 
** Since no trend was observed for median survival time as related to dose of leucine 
dehydrogenase, the 2 saline controls were pooled as one group, compared with the 
4 treatment groups (doses 4,4,8 and 16 n&g/day). 
Taper liver tumor. Even at a dose as high as 16 mg/kg/ 
day no antitumor effect was observed (table 1). 
Inspection of the organs revealed no gross toxicity 
resulting from treatment of mice with leucine 
dehydrogenase. Oki et al. [l] reported that treatment 
of DD mice bearing an Ehrlich ascites carcinoma with 
B. sphericus leucine dehydrogenase (S.A. = 100) at 
a dose of 1 or 4 mg/kg/day for 14 days resulted in a 
greater than 100% increase in survival time in treated 
animals, It should be noted that in our experiments 
mice were inoculated with 1 X 10’ ascites cells, while 
Oki et al. used 2 X IO6 cells. It is, however, improbable 
that the greater number of tumor cells is responsible 
for the therapeutic ineffectiveness of leucine dehydro- 
genase in our studies, since there was no decrease 
in plasma leucine levels in enzyme-treated mice 
(table 2). Oki et al. [I] did not determine the effect 
of treatment with leucine dehydrogenase onamino 
acid levels in the host’s circulation. 
The results described in the present communication 
appear to be consistent with the kinetical properties 
of the enzyme and the equilibrium constant of the 
reaction in vitro. The enzyme requires NAD as an 
essential cofactor [2 ] the concentration of which is 
negligible in serum. We have found that the pH 
optimum of the reaction is between 10 and 12 and 
the enzyme activity at physiological pH (7.4) is less 
than 5% of the activity obtained under the standard 
assay conditions (pH 11.3). Sanwal and Zink [6 ] 
reported the equilibrium constant for the reaction, 
Table 2 
Effect of leuchte dehydrogenase treatment on plasma ammo acid levels 
Experiment No. Enzyme dose X days 
W/kg/day) 
Plasma leucine concentration 
(nmoles/ml) 
Hours post enzyme injection 
1* 
2** 
4x 1 
Saline control 
4x5 
8X5 
16 x 5 
0 (Control) I 5 24 
74 99 81 94 
90 
70 
83 
76 
* Normal mice. 
** Tumor-bearing mice. 
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k’ eq = (NADH) (cu-ketoisocaproate) (NH,) (H3 This work was supported by the National Cancer 
(NAD) (L-leucine) Institute (Grant CA-08748). 
to be 11.1 X lo-r4 (moles/l.)2. Taking into account 
the physiological pH (7.4) and the concentration of 
ammonia in serum (approximately 3X lo-’ M) [7,8], 
the equilibrium concentration of the other four 
reactants might be expected to satisfy the equation 
described below: 
(NADH) eq (o-ketoisocaproate) q= 9.3 X 10m2. 
(MD) eq (Lleucine) eq 
It is apparent that the breakdown of leucine will not 
occur readily in serum in the presence of B. sphaerim 
leucine dehydrogenase. 
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